MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Country |
 USA |
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
250 M |
Market Cap[1] |
$ 1.14 B |
EBITDA (LTM) |
$ -107 M |
P/E (LTM) |
-12.58 |
P/S (LTM) |
157.64 |
EPS (LTM) |
-0.36 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Alector
ALEC
|
$ 2.19 | -9.77 % | $ 226 M | Nasdaq Global Select Market,SPB | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Cabaletta Bio
CABA
|
$ 3.34 | 0.45 % | $ 3.9 M | Nasdaq Global Select Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Codexis
CDXS
|
$ 1.02 | 1.49 % | $ 74.9 M | Nasdaq Global Select Market | USA |
 |
AbCellera Biologics
ABCL
|
$ 3.74 | 3.6 % | $ 1.12 B | Nasdaq Global Select Market |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Cerus Corporation
CERS
|
$ 2.6 | 1.37 % | $ 480 M | Nasdaq Global Market | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
Cellectis S.A.
CLLS
|
$ 3.87 | -0.39 % | $ 116 M | Nasdaq Global Market | France |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
CNS Pharmaceuticals
CNSP
|
$ 3.23 | 2.22 % | $ 1.23 M | Nasdaq Capital Market | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Collegium Pharmaceutical
COLL
|
$ 41.75 | 0.19 % | $ 1.32 B | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 36.14 | 1.23 % | $ 3.75 B | Nasdaq Capital Market,SPB | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Amarin Corporation plc
AMRN
|
$ 13.98 | 1.27 % | $ 5.7 B | Nasdaq Global Market |  Irlanda |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
$ 23.77 | 2.99 % | $ 2.91 B | Nasdaq Capital Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 8.41 | -1.87 % | $ 36.4 M | Nasdaq Global Market | USA |
 |
Cardiff Oncology
CRDF
|
$ 1.94 | 0.01 % | $ 130 M | Nasdaq Capital Market | USA |
 |
Curis
CRIS
|
$ 1.1 | -3.51 % | $ 6.94 M | Nasdaq Global Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
CorMedix
CRMD
|
$ 7.16 | 0.42 % | $ 364 M | Nasdaq Global Market | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
|
Champions Oncology
CSBR
|
$ 6.14 | 3.89 % | $ 83.9 M | Nasdaq Capital Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.72 | -2.34 % | $ 4.84 M | Nasdaq Capital Market | USA |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | USA |
 |
Altimmune
ALT
|
$ 4.21 | -2.32 % | $ 299 M | Nasdaq Global Market | USA |
 |
CEL-SCI Corporation
CVM
|
$ 3.88 | -8.92 % | $ 247 M | NYSE American,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.